Monitoring response to treatment in melanoma patients: Potential of a serum glycomic marker

International Journal of Cancer

Volumn 122, Issue 6, 2008, Pages 1374-1383

  Selvan, Senthamil R ^a   Dillman, Robert O ^a   Fowler, Abner W ^a   Carbonell, Denysha J ^a   Ravindranath, Mepur H ^b  

^a HOAG MEMORIAL HOSPITAL PRESBYTERIAN   (United States)

^b JOHN WAYNE CANCER INSTITUTE   (United States)

Author keywords

Antiganglioside IgM antibodies; Autologous vaccine therapy; Dendritic cells; Glycomic markers; Melanoma; Serum total gangliosides

Indexed keywords

BIOLOGICAL MARKER; DENDRITIC CELL VACCINE; GAMMA INTERFERON; GANGLIOSIDE; GANGLIOSIDE ANTIBODY; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN M ANTIBODY;

ADULT; AGED; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; COCULTURE; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE MARKER; DOWN REGULATION; FEASIBILITY STUDY; FEMALE; HUMAN; HUMAN CELL; MALE; MELANOMA; OVERALL SURVIVAL; PATIENT MONITORING; PRIORITY JOURNAL; TREATMENT RESPONSE; TUMOR CELL; UPREGULATION;

ADULT; AGED; COHORT STUDIES; FEMALE; GANGLIOSIDES; HUMANS; IMMUNOTHERAPY; MALE; MELANOMA; MIDDLE AGED; MONITORING, PHYSIOLOGIC; NEOPLASM METASTASIS; TUMOR MARKERS, BIOLOGICAL;

EID: 39649091418     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.23155     Document Type: Article

References (40)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007;57:43-66.
2. Tsao H, Atkins MB, Sober AJ. Management of cutaneous melanoma. N Engl J Med 2004;351:998-1012.
3. Fang D, Nguyen TK, Leishear K, Finko R, Kulp AN, Hotz S, Van Belle PA, Xu X, Elder DE, Herlyn M. A tumorigenic subpopulation with stem cell properties in melanomas. Cancer Res 2005;65:9328-37.
4. Tsuchida T, Ravindranath MH, Saxton RE, Irie RF. Gangliosides of human melanoma: altered expression in vivo and in vitro. Cancer Res 1987;47:1278-81.
5. Kong Y, Li R, Ladisch S. Natural forms of shed tumor gangliosides. Biochim Biophys Acta 1998;1394:43-56.
6. Bergelson LD. Serum gangliosides as endogenous immunomodulators. Immunol Today 1995;16:483-6.
7. Anichini A, Mortarini R, Nonaka D, Molla A, Vegetti C, Montaldi E, Wang X, Ferrone S. Association of antigen-processing machinery and HLA antigen phenotype of melanoma cells with survival in American Joint Committee on Cancer stage III and IV melanoma patients. Cancer Res 2006;66:6405-11.
8. Hakansson L, Fredman P, Svennerholm L. Gangliosides in serum immune complexes from tumor-bearing patients. J Biochem 1985;98:843-9.
9. Valentino LA, Ladisch S. Localization of shed human tumor gangliosides: association with serum lipoproteins. Cancer Res 1992;52:810-14.
10. Tonegawa Y, Hakomori SI. "Ganglioprotein and globoprotein": the glycoproteins reacting with anti-ganglioside and anti-globoside antibodies and the ganglioprotein change associated with transformation. Biochem Biophys Res Commun 1997;76:9-17.
11. Dolo V, Li R, Dillinger M, Flati S, Manela J, Taylor BJ, Pavan A, Ladisch S. Enrichment and localization of ganglioside G(D3) and caveolin-1 in shed tumor cell membrane vesicles. Biochim Biophys Acta 2000;1486:265-74.
12. Ravindranath MH, Hsueh EC, Verma M, Ye W, Morton DL. Serum total ganglioside level correlates with clinical course in melanoma patients after immunotherapy with therapeutic cancer vaccine. J Immunother 2003;26:277-85.
13. Perez CA, Ravindranath MH, Soh D, Gonzales A, Ye W, Morton DL. Serum anti-ganglioside IgM antibodies in soft tissue sarcoma: clinical prognostic implications. Cancer J 2002;8:384-94.
14. Ravindranath MH, Muthugounder S, Presser N, Ye X, Brosman S, Morton DL. Endogenous immune response to gangliosides in patients with confined prostate cancer. Int J Cancer 2005;116:368-77.
15. Santin AD, Ravindranath MH, Bellone S, Muthugounder S, Palmieri M, O'Brien TJ, Roman J, Cannon MJ, Pecorelli S. Increased levels of gangliosides in the plasma and ascitic fluid of patients with advanced ovarian cancer. BJOG 2004;111:613-18.
16. Ravindranath MH, Muthugounder S, Presser N, Selvan SR, Santin AD, Bellone S, Saravanan TS, Morton DL. Immunogenic gangliosides in human ovarian carcinoma. Biochem Biophys Res Commun 2007;353:251-8.
17. Ravindranath MH, Wood TF, Soh D, Gonzales A, Muthugounder S, Perez C, Morton DL, Bilchik AJ. Cryosurgical ablation of liver tumors in colon cancer patients increases the serum total ganglioside level and then selectively augments anti-ganglioside IgM. Cryobiology 2002;45:10-21.
18. Chu KU, Ravindranath MH, Gonzales A, Nishimoto K, Tam WY, Soh D, Bilchik A, Katopodis N, Morton DL. Gangliosides as targets for immunotherapy for pancreatic adenocarcinoma. Cancer 2000;88:1828-36.
19. Dillman R, Selvan S, Schiltz P, Peterson C, Allen K, De Priest C, McClay E, Barth N, Sheehy P, De Leon C, Beutel L. Phase-I/II trial of melanoma patient-specific vaccine of proliferating autologous tumor cells, dendritic cells, and GM-CSF: planned interim analysis. Cancer Biother Radiopharm 2004;19:658-65.
20. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000;92:205-16.
21. Nayak SK, Dillman RO. Establishment of multiple tumor cell lines from a patient with melanoma: a simple method to control fibroblast growth. Clin Biotechnol 1991;3:237-42.
22. Dillman RO, Nayak SK, Beutel LD. Establishing in vitro cultures of autologous tumor cells for use in active specific immunotherapy. J Immunother 1993;14:65-9.
23. Selvan RS, Pappas TN, Ward FE. Lack of evidence for MHC-unrestricted (atypical) recognition of mucin by mucinous pancreatic tumor-reactive T-cells. Br J Cancer 2000;82:691-701.
24. Dillman RO, De Leon C, Beutel LD, Barth NM, Schwartzberg LS, Spitler LE, Garfield DH, O'Connor AA, Nayak SK. Short-term autologous tumor cell lines for the active specific immunotherapy of patients with metastatic melanoma. Crit Rev Oncol Hematol 2001;39:115-23.
25. Selvan SR, Sheridan M, Fowler AW, Dillman RO. Characterization of autologous melanoma cell lines for vaccine therapy: pattern of expression of tumor-associated antigens. Proc Am Assoc Cancer Res 2004;45:286.
26. Nayak SK, Schiltz PM, Dillman RO. Modulation of renal carcinoma cells in vitro: comparison after transduction with retroviral vector containing a human IFN-γ gene versus incubation with soluble IFN-γ. J Interferon Cytokine Res 1999;19:49-58.
27. Van den Aardweg GJ, Naus NC, Verhoeven AC, de Klein A, Luyten GP. Cellular radiosensitivity of primary and metastatic human uveal melanoma cell lines. Invest Ophthalmol Vis Sci 2002;43:2561-5.
28. Schiltz PM, Malone C, Spencer KS, Dillman RO. Cryopreserved dendritic cells maintain phenotype and ability to elicit an allogeneic response post recovery. J Immunother 2000;23:601.
29. Tsuchida T, Saxton RE, Morton DL, Irie RF. Gangliosides of human melanoma. J Natl Cancer Inst 1987;78:45-54.
30. Ravindranath MH, Tsuchida T, Morton DL, Irie RF. Ganglioside GM3:GD3 ratio as an index for the management of melanoma. Cancer 1991;67:3029-35.
31. Ravindranath MH, Ravindranath RM, Morton DL, Graves MC. Factors affecting the fine specificity and sensitivity of serum anti-ganglioside antibodies in ELISA. J Immunol Methods 1994;169:257-72.
32. Ravindranath MH, Muthugounder S, Saravanan TS, Presser N, Morton DL. Human antiganglioside autoantibodies: validation of ELISA. Ann N Y Acad Sci 2005;1050:229-42.
33. Livingston PO, Wong GY, Adluri S, Tao Y, Padavan M, Parente R, Hanlon C, Calves MJ, Helling F, Ritter G, Oettgen HF, Old LJ. Improved survival in stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside. J Clin Oncol 1994;12:1036-44.
34. Irie RF, Ravindranath MH. Gangliosides as targets for monoclonal antibody therapy of cancer. In: Borrebaeck CAK, Larrick JW, eds. Therapeutic monoclonal antibodies. New York: Stockton, 1990. 75-94.
35. Portoukalian J, Zwingelstein G, Abdul-Malak N, Dore JF. Alteration of gangliosides in plasma and red cells of humans bearing melanoma tumors. Biochem Biophys Res Commun 1978;85:916-20.
36. 3 shedding by human malignant melanoma cells. Int J Cancer 1989;44:155-60.
37. Alessandri G, Filippeschi S, Sinibaldi P, Mornet F, Passera P, Spreafico F, Cappa PM, Gullino PM. Influence of gangliosides on primary and metastatic neoplastic growth in human and murine cells. Cancer Res 1987;47:4243-7.
38. Ladisch S, Kitada S, Hays EF. Gangliosides shed by tumor cells enhance tumor formation in mice. J Clin Invest 1987;79:1879-82.
39. Takahashi K, Ono K, Hirabayashi Y, Taniguchi M. Escape mechanisms of melanoma from immune system by soluble melanoma antigen. J Immunol 1988;140:3244-8.
40. Ravindranath MH, Yesowitch P, Sumobay C, Morton DL. Glycoimmunomics of human cancer: current concepts and future perspectives. Future Oncol 2007;3:201-14.